Galectin-3 binds to the RGD-binding site in a glycan-independent manner and to the allosteric site and activates integrins αvβ3, αIIbβ3, and α5β1

Galectin-3 (Gal3) is one of the most pro-inflammatory proteins and a biomarker of inflammatory diseases and cancer. Previous studies showed that Gal3 binds to αv and β1 integrins but it is unclear how Gal3 binds to integrins. Here, we show that Gal3 bound to soluble αvβ3 and αIIbβ3 integrins in 1 mM Mn2+ in cell-free conditions in a glycan-independent manner. Docking simulation predicts that Gal3 binds to the classical RGD-binding site (site 1) of αvβ3, but the predicted Gal3-binding site does not include galactose-binding site. RGDfV or eptifibatide inhibited Gal3 binding to αvβ3 and αIIbβ3, respectively, but lactose, pan-galectin inhibitor, did not inhibit Gal3 binding to integrins. Point mutations of the predicted site 1 binding interface of Gal3 effectively inhibited Gal3 binding to site 1. Site 2 is involved in pro-inflammatory signaling (e.g., TNF and IL-6 secretion) and we previously showed that pro-inflammatory cytokines (e.g., CCL5 and TNF) bind to site 2 and allosteric integrin activation. Docking simulation predicts that Gal3 binds to site 2 of αvβ3 and α5β1. We found that Gal3 induced allosteric activation of soluble integrins αvβ3, αIIbβ3, and α5β1 in 1 mM Ca2+ in cell-free conditions. Point mutations in the predicted site 2-binding interface inhibited Gal3-induced integrin activation, suggesting that Gal3 binding to site 2 is required for Gal3-induced integrin activation. Known anti-inflammatory agents, Ivermectin, NRG1, and FGF1 inhibited integrin activation induced by Gal3 in αvβ3 and αIIbβ3. These findings suggest that Gal3 binding to site 2 may be a potential mechanism of pro-inflammatory and pro-thrombotic action of Gal3.

• Publication year

  2026

• Venue

  bioRxiv

• Publication date

  2026-02-07

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.64898/2026.02.05.704096PMID 41676549PMCID 12889656
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy.

  2024cited by this paper
• Trophoblast cell surface antigen-2 phosphorylation triggered by binding of galectin-3 drives metastasis through down-regulation of E-cadherin

  2023cited by this paper
• Galectin-3 Binding to α5β1 Integrin in Pore Suspended Biomembranes

  2022cited by this paper
• αvβ1 integrin is enriched in extracellular vesicles of metastatic breast cancer cells: A mechanism mediated by galectin‐3

  2022cited by this paper
• Galectin 3 enhances platelet aggregation and thrombosis via Dectin-1 activation: a translational study.

  2022cited by this paper
• Antibody-mediated blockade for galectin-3 binding protein in tumor secretome abrogates PDAC metastasis

  2021cited by this paper
• Integrin activation by the lipid molecule 25-hydroxycholesterol induces a proinflammatory response

  2019cited by this paper
• Stromal cell-derived factor-1 (CXCL12) activates integrins by direct binding to an allosteric ligand-binding site (site 2) of integrins without CXCR4.

  2018cited by this paper
• The Many Roles of Galectin-3, a Multifaceted Molecule, in Innate Immune Responses against Pathogens

  2017cited by this paper
• Galectin-3 enhances extracellular matrix associations and wound healing in monkey corneal epithelium.

  2015cited by this paper
• The Chemokine Fractalkine Can Activate Integrins without CX3CR1 through Direct Binding to a Ligand-Binding Site Distinct from the Classical RGD-Binding Site

  2014cited by this paper
• Direct Binding of the EGF-like Domain of Neuregulin-1 to Integrins (αvβ3 and α6β4) Is Involved in Neuregulin-1/ErbB Signaling*

  2010cited by this paper
• Pro-inflammatory Secretory Phospholipase A2 Type IIA Binds to Integrins αvβ3 and α4β1 and Induces Proliferation of Monocytic Cells in an Integrin-dependent Manner*

  2008cited by this paper
• The integrins

  2007cited by this paper
• Integrin and Growth Factor Receptor Crosstalk

  2001cited by this paper
• Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis.

  1999cited by this paper
• Ligand occupancy of the alpha-V-beta3 integrin is necessary for smooth muscle cells to migrate in response to insulin-like growth factor.

  1996cited by this paper
• Requirement of vascular integrin alpha v beta 3 for angiogenesis.

  1994cited by this paper

• No citing papers are available for this paper.